Public disclosures

AVIR insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-192026-11-19

53,372 shares/units

SEC 4Follow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 53372 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-19

21,628 shares/units

SEC 4Follow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 187990 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $3.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-192026-11-19

≈ $89,220.65

22,619 shares/units

SEC 4Follow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 210609 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-192026-11-19

53,372 shares/units

SEC 4Follow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 157237 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-19

≈ $27,189.82

6,741 shares/units

SEC 4Follow
Lucidi Bruno

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 163978 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-19

21,628 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 149830 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.04. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-192026-11-19

≈ $35,298.38

8,750 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

18,252 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 18252 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

8,720 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 26972 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

48,028 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

≈ $72,099.05

18,252 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 176832 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

18,252 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

≈ $35,155.55

8,720 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 167300 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

8,720 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

≈ $60,840.35

14,254 shares/units

SEC 4Follow
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 172834 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

48,028 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement